Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00097383 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: ALIMTA plus Epirubicin

Sponsor

Eli Lilly and Company